Letetresgene autoleucel

乐基仑赛

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLetetresgene autoleucel
Drug Alias NameNY-ESO-c259TNY-ESO SPEAR T-cell therapy - GlaxoSmithKlineNY-ESO-1c259-TCR-transduced-lymphocytesNY-ESO-1-specific T-cells - AdaptimmuneNY-ESO-1c259-TCR-transduced-T-cells +[14] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived +[4] 
Mechanisms of ActionImmunostimulantsCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsMultiple Myeloma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesUs WorldmedsUSWM LLC
Inactive CompaniesAdaptimmune LlcGlaxosmithkline Plc
Active IndicationsNeoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A